The company exhibits strong sales growth but inconsistent profit growth. Compounded Sales Growth has been robust, with the TTM at 30%. However, the Compounded Profit Growth TTM is -26%. Quarterly results show a significant increase in sales, with a YOY Sales Growth % of 31.16% in Sep 2024, but YOY Profit Growth % is -5.60% for the same period. This indicates sales are growing faster than profits. Over the years sales have improved but profit have been volatile.

Astrazeneca Pharma India Ltd. demonstrates strong capital efficiency with healthy Return on Capital Employed (ROCE) and Return on Equity (ROE). The current ROCE is 33.94% and ROE is 24.95%, indicating effective utilization of capital and shareholder funds. These metrics suggest the company is generating substantial returns from its investments. This showcases the management's effectiveness in allocating capital and generating returns for shareholders. The following table summarizes the ROCE and ROE trends over the past few years:

Astrazeneca Pharma India Ltd. exhibits a financially healthy and prudent approach to debt management. The company maintains a low Debt/Equity Ratio, with minimal borrowings, indicating a conservative approach to leverage. The interest coverage ratio is strong, ensuring the company can comfortably meet its interest obligations. Dividend payouts have been consistently shared with shareholders. This reflects responsible financial stewardship and a commitment to shareholder returns. The company's financial prudence contributes to its stability and reduces its vulnerability to economic downturns. The following table summarizes the key financial health metrics:

Working capital management shows mixed efficiency. Debtor Days have increased from 39 days in Mar 2023 to 43 days in Mar 2024, while Inventory Days decreased from 193 days to 140 days. The Cash Conversion Cycle has improved significantly from 1 day in Mar 2023 to 62 days in Mar 2024. Fixed Asset Management appears strategic, with consistent investments in Gross Block and CWIP, indicating a focus on long-term growth. The company's ability to optimize working capital cycles and strategically invest in fixed assets will be vital for sustaining competitiveness and supporting future growth.

There is no indication of off-balance sheet exposure.

There is no indication of contingent liability.

There is no indication of accounting quality red flags.

Quarterly results show volatility in profit growth and OPM. YOY Profit Growth % varies significantly, ranging from -46.08% in Dec 2023 to 167.30% in Jun 2023. OPM % also fluctuates, from 5% in Dec 2023 to 23% in Jun 2023. This variability indicates potential operational inefficiencies and challenges in maintaining consistent profitability.